baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

QIAGEN NV/ NL0015001WM6 /

31/05/2024 17:23:04	Chg. -	Volume	Bid17:23:24	Ask13:02:05	Market Capitalization	Dividend Y.	P/E Ratio
39.49EUR	-	651 Turnover: 25,612.19	-Bid Size: -	-Ask Size: -	9.43 bill.EUR	-	-

GlobeNewswire 06/06 QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...

GlobeNewswire 05/06 QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...

GlobeNewswire 03/06 QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...

GlobeNewswire 30/05 QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...

GlobeNewswire 29/05 QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...

GlobeNewswire 22/05 deepull appoints Didier Deltort to its Board of Directors

GlobeNewswire 14/05 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 13/05 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 07/05 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 02/05 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 29/04 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

GlobeNewswire 25/04 deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...

GlobeNewswire 24/04 QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...

GlobeNewswire 18/04 deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...

GlobeNewswire 09/04 QIAGEN N.V. to release results for Q1 2024 and hold webcast

GlobeNewswire 03/04 QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...

GlobeNewswire 25/03 QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration a...

GlobeNewswire 18/03 QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosi...

GlobeNewswire 11/03 QIAGEN announces Form 20-F annual report filing for 2023 results

GlobeNewswire 27/02 QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

GlobeNewswire 27/02 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 15/02 QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Plati...

GlobeNewswire 06/02 QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved op...

TeleTrader 06/02 Europe higher at close, economic prints in spotlight

QIAGEN NV/ NL0015001WM6 /

If you wish to receive reply to your feedback, please provide your email address.